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We investigated the clinicopathological features of62 patients with transitional cell carcinoma of 
the renal pelvis and/or ureter who underwent total nephroureterectomy at our department from April， 
1987 to October， 2000. The patients consisted of 48 males and 14 females， with a mean age of 67 
years， ranging from 46 to 86 years. The mean follow-up period was 40 months. 
The 1-， 3-and 5-year cause-specific survival rates (Kaplan-Meier's method) for al ofthe patients 
were 90.8， 82.9%， and 68.6%， respectively. The prognostic significance ofthe 5 pathological factors 
(grade， pT， pV， pL and pN) were evaluated. All these factors affected the survival rates significantly 
in univariate analysis using the generalized Wilcoxon test. According to multivariate analysis by the 
Cox proportional hazard model， the most influential prognostic factor was grade. 
(Acta Urol. Jpn. 48: 735-739， 2002) 



































た.このうち 1回以上 Papanicolaouclass IVあるい
はclassVを示した症例を陽性例とすると，陽性例は
36例 (58.1%)であった.また陽性例と疑陽性 (class
















を Fig.3に示した. gradeを含め stage(pT) ， ve-
nous invasion (p V)， 1ymphatic invasion (pL) ， 





















脈管浸潤の割合で示した (Tab1e1). pTa， pTlの群





いたが， pNO: 36例 (78.3%)，pN1 : 2例 (4.3%)，
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Fig. 3. Survival rate according to grade: G. 
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Table 3. Multivariate analysis (Cox proportional hazard model) of prognostic factors for survival 
Prognostic factor Category advantage/disadvantage Risk ratio (95% Cl) p value 
Grade Grade 1-2/grade 3 3.976 (1.014-15.587) 0.04 
Stage pTis-pT!/pT2-pT4 1.550 (0.452-5.318) 0.48 
Venous invasion pVO/pV1 3.468 (0.899-13.371) 0.07 















































































grade， stage， pV， pL，について Cox比例ハザー
ドモデルによる多変量解析を行い，各因子の予後への
関与の程度を比較した.結果は gradeのみが有意差














? ?? ? ?
1) 腎孟尿管癌62手術症例の臨床的検討を行った.
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